TransMedics Group, Inc.
TransMedics Group, Inc.
Your view on TMDX
Overview
What the company does, where it operates, and who runs it.
About TransMedics Group, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Waleed H. Hassanein
- Headquarters
- 200 Minuteman Road, Andover, MA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Waleed H. Hassanein
- Headquarters
- 200 Minuteman Road, Andover, MA, US
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for TransMedics Group, Inc., and the rating behind it. TMDX last traded at $70.63, 15.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for TransMedics Group, Inc.. Starting points for TransMedics Group, Inc.: P/E 15.8, EPS $4.39, beta 1.93 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for TransMedics Group, Inc.. TransMedics Group, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for TransMedics Group, Inc.. Trailing twelve-month EPS for TransMedics Group, Inc. stands at $4.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for TransMedics Group, Inc.. TransMedics Group, Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
TransMedics Group, Inc. valued side by side against its closest peers. TransMedics Group, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold TransMedics Group, Inc., and how their positions are changing. At a $2.45B market value, institutional positions materially move TransMedics Group, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by TransMedics Group, Inc. executives and directors. Shares of TransMedics Group, Inc. have traded between $55.00 and $145.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming TransMedics Group, Inc.. TransMedics Group, Inc. is a $2.45B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming TransMedics Group, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for TransMedics Group, Inc.. Coverage tracks TransMedics Group, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.